In the original version of this article, in the section under the subheading "CNS-specific NK cells in disease" on page 668, the humanized antibody daclizumab was incorrectly described as being specific for the IL-2 receptor β-chain (CD122). The corrected sentence now reads: "These findings might be relevant to the mode of action of daclizumab, a humanized antibody specific for the IL-2 receptor α-chain (CD25)". The authors apologize for this error.
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